Concert Pharma (CNCE) Misses Q1 EPS by 4c

Concert Pharma (NASDAQ: CNCE) reported Q1 EPS of ($0.48), $0.04 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $2.7 million.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• Commercial Metals (CMC) Tops Q3 EPS by 3c, Beats on Revenue
• McCormick & Co. (MKC) Tops Q2 EPS by 10c ; Offers Guidance